| Literature DB >> 21530512 |
Changchun Zhou1, Jibing Liu, Yang Li, Li Liu, Xiaojiao Zhang, Cheng-yuan Ma, Shu-cheng Hua, Ming Yang, Qipeng Yuan.
Abstract
Hepatocellular carcinoma (HCC) is a complex and heterogeneous tumor with poor prognosis. Sorafenib, a multikinase inhibitor, has been widely used to treat patients with advanced HCC in clinic. We postulated that microRNAs (miRNA) might be involved in HCC target-chemotherapy with sorafenib. MiRNA profile of HepG2 was evaluated after cells were treated with vehicle or sorafenib and alterations in miRNA expression occurred with 14 miRNAs. MiR-1274a, which is up-regulated by sorafenib, could significantly repress expression of ADAM9, a protease that is involved in sorafenib target-therapy of HCC, in HCC cells. Taken together, our data emphasizes a new miRNA-based mechanism of sorafenib antitumor therapy.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21530512 DOI： 10.1016/j.febslet.2011.04.040
Source DB: PubMed Journal: FEBS Lett ISSN： 0014-5793 Impact factor: 4.124